前列腺增生与前列腺癌的经直肠超声彩色血流平均密度对比研究

A comparative study of mean color blood flow density in benign prostate hypertrophy and prostate cancer with transrectal ultrasound-MCVD

目的:探讨经直肠超声彩色血流平均密度(TRUS-MCVD)对前列腺增生和前列腺癌的鉴别诊断价值。材料和方法:应用经直肠彩色血流能量成像(TR-CPA)检测60例前列腺增生和22例前列腺癌患者,计算前列腺病变区域单位面积的彩色血流平均密度(MCVD),并做组间对比;其中前列腺癌临床分期的MCVD做组间对比。结果:前列腺增生组MCVD为(0.0857±0.0348)小于前列腺癌组(0.2400±0.0851);前列腺癌组D期MCVD(0.3488±0.0522)显著高于A期MCVD(0.2170±0.0354)、B期MCVD(0.2231±0.0814)、C期MCVD(0.2252±0.0924)(P<0.05)。结论:TRUS-MCVD可做为前列腺增生和前列腺癌的鉴别诊断依据,并能于术前评价前列腺癌的预后。

Objective： To explore the value of transrectal ultrasound-mean color vessel density（TRUS-MCVD） in benign prostate hypertrophy（BPH） and prostate cancer（PCa）. Materials and Methods： Twenty-two cases of PCa and 60 cases of BPH were examined with transrectal color power angiography（TR-CPA）, MCVD of focal lesions were calculated with Auto CAD2004 software and had been compared with each other. Results of PCa were compared with their clinical stages. Results： MCVD of PCa group were significantly higher than that of the BPH group（0.2400±0.0851 vs 0.0857±0.2867, P〈0.01）. There was significantly difference between stage D and stage A, B, C in PCa（0.3488±0.0522 vs 0.2170±0354, 0.2231±0814, 0.2252±0.0924, P〈0.05）. Conclusion： The TRUS-MCVD can provide objective evidence for differential diagnosis of PCa and BPH, moreover, it is helpful in predicting the prognosis of PCa before treatment.